Medical Progress Today
mpt home | sign up

Volume 2, Number 38
October 20, 2005


PRINTER FRIENDLY

Commentary

Idealistic, Its Not: Consumers Union wrong to tout Prop.
The San Diego Union-Tribune, 10-14-05

The Tribune takes Consumers Union to task for promoting Proposition 79, an California special election initiative, backed by unions for reasons entirely unrelated to public health.

In refusing to take advertising for fear it would taint product reviews, Consumer Reports magazine has for decades been an admirable bastion of journalistic integrity. That's why we were surprised and disappointed to see the magazine's parent organization, Consumers Union, lending its good name to a politically driven initiative on the Nov. 8 special election ballot.
Proposition 79 is a complex measure that would create a new government bureaucracy that supposedly would help 8 million to 10 million Californians secure discounts on prescription drugs by negotiating bulk purchases from pharmaceutical companies. To force firms to comply, they could face punitive lawsuits charging their profits are unreasonably high, a definition so elastic that it can only be seen as an open invitation for trial-lawyer avarice.
It seems to us that this proposition is qualitatively different from other crusades the Consumers Union has supported, such as demanding more financial privacy or calling for fuller disclosure of credit card fees. This initiative isn't part of a grand push to overhaul health care and make it more consumer-friendly. Instead, it is a poorly drafted measure whose own proponents tout more in terms of cheap populism a promise to save millions of voters billions of dollars than reform.

The problem, as Alan Murray pointed out in another article we highlight this week, is that pharmaceuticals are seen less as commodities than as public goods, which consumers instinctively think ought to be free. This (incorrect and dangerous) perception leaves plenty of room for demagoguery, which the proponents of Proposition 79 are exploiting to good effect.

Source: http://www.signonsandiego.com/uniontrib/20051014/news_1ed14bottom1.html


Medical Progress Today is published by the Center for Medical Progress at the Manhattan Institute for Policy Research.

For more information about Medical Progress Today, please contact the managing editor, Paul Howard, at phoward@manhattan-institute.org, or via telephone at 212.599.7000.

Press inquiries regarding Medical Progress Today can be directed to the Communications Department, at communications@manhattan-institute.org, or via telephone at 212.599.7000.

If you would like to unsubscribe, please reply to us and type "Unsubscribe" in the subject line.

In this week's issue:

spotlight

Bare-Knuckle Politics Leads to Bad Public Policy

news

Hurdles ahead for makers of gene-based medicine
Links with pharma groups blossom
Bayer Offers New Antibiotic with Promise in Fight on TB

commentary

Roche Feels the Highs and Lows of Feverish Demand for Tamiflu
First, Do No Harm
Drugs companies are not on the same level as arms dealers
Idealistic, Its Not: Consumers Union wrong to tout Prop.
Center for Medical Progress 
Copyright Manhattan Institute for Policy Research
52 Vanderbilt Avenue
New York, NY 10017
(212) 599-7000
mpt@manhattan-institute.org